The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells.

Abstract

INTRODUCTION:

Previous studies suggested that estrogen receptor alpha (ERα) plays an important role in the chemoresistance of breast cancers. However, large random trials failed to demonstrate any benefit of the concurrent estrogen antagonist tamoxifen on the chemotherapy efficacy. Thus, in the present study, the importance of the role of ERα in the chemoresistance of breast cancer cells was investigated.

METHODS:

The ERα-transfected Bcap37 cells and natural ERα-positive T47D breast cancer cells were treated using chemotherapeutic agents with or without 17-beta estradiol (E2) pretreatment. Their viabilities were assessed using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assays. The dead cell rates were determined using propidium iodide dye exclusion tests, and the expression levels of Bcl-2 and Bax were detected through Western blot analysis. The effects of E2 on the growth of breast cancer cells were also determined via cell growth curve and cell cycle analysis.

RESULTS:

ERα activation by E2 increased the sensitivity of natural ERα-positive T47D breast cancer cells to chemotherapeutic agents. However, the increase in ERα expression in ERα-negative Bcap37 breast cancer cells also significantly increased their resistance. These phenomena cannot be explained by asserting that ERα mediated the chemoresistance of breast cancer cells by regulating the expression of Bcl-2 and Bax. Our findings show that ERα activation upregulated the expression of Bcl-2 in natural ERα-positive T47D breast cancer cells, whereas ERα activation by E2 downregulated and upregulated the Bcl-2 and Bax expression levels, respectively, in ERα-transfected Bcap37 cells. This phenomenon was due to the influence of ERα on the growth of breast cancer cells. Specifically, ERα activation enhanced the growth of natural ERα-positive breast cancer cells and thus increased their sensitivity to chemotherapeutic agents. However, ERα activation also inhibited the growth of ERα-transfected Bcap37 cells and increased the resistance of cancer cells to chemotherapeutic agents. Chemoresistance of ERα-transfected Bcap37 cells was only due to the specific growth inhibition by E2, which is not applicable to common ERα-positive breast cancer cells.

CONCLUSIONS:

Although ERα was associated with chemoresistance of breast cancers, ERα itself did not mediate this resistance process.

• Authors: Zhinong Jiang, Junlan Guo, Jianguo Shen, Mei Jin, Shuduo Xie, Linbo Wang
• Journal: Journal of experimental & clinical cancer research : CR (J Exp Clin Cancer Res) Vol. 31 Pg. 42 (May 03 2012) ISSN: 1756-9966 [Electronic] England
• PMID: 22553917 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• BAX protein, human
• Estrogen Antagonists
• Estrogen Receptor alpha
• PHB2 protein, human
• Prohibitins
• Proto-Oncogene Proteins c-bcl-2
• bcl-2-Associated X Protein
• Fulvestrant
• Estradiol

Topics

• Antineoplastic Agents (pharmacology)
• Breast Neoplasms (drug therapy, genetics, metabolism, pathology)
• Cell Growth Processes (drug effects, physiology)
• Cell Line, Tumor
• Drug Resistance, Neoplasm
• Estradiol (analogs & derivatives, pharmacology)
• Estrogen Antagonists (pharmacology)
• Estrogen Receptor alpha (genetics, metabolism)
• Female
• Fulvestrant
• Gene Expression Regulation, Neoplastic
• Humans
• Prohibitins
• Proto-Oncogene Proteins c-bcl-2 (biosynthesis, genetics)
• Transfection
• Up-Regulation (drug effects)
• bcl-2-Associated X Protein (biosynthesis, genetics, metabolism)